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1. Introduction
Acute respiratory infections cause 4.25 million deaths worldwide ev-
ery year.1 A critical need exists for the development of efficacious 
intranasal vaccines against respiratory pathogens capable of induc-
ing robust and protective mucosal immunity. In this regard, there is 
growing interest in the development of vaccines that can be easily 
administered to the site of infection in order to elicit both local and 
systemic immune responses.2–5
The study of alveolar macrophages (AMφ), a type of antigen 
presenting cell (APC) in the respiratory tract, is central to the de-
velopment of intranasal vaccines. AMφ constitute more than 80% 
of the total cells obtained by bronchoalveolar lavage of a healthy 
individual and they constitutively migrate from the lung to the 
draining lymph nodes (DLN).6–8 Indeed, AMφ containing bacte-
ria appear in the pulmonary DLN prior to the onset of pathogen-
induced DC migration, thereby making them integral to the estab-
lishment of protective pulmonary immune responses.6 AMφ are 
equipped to detect pathogens with the aid of pattern recognition re-
ceptors (PRRs) that recognize pathogen-associated molecular pat-
terns (PAMPs).9 One family of PRRs found on AMφ, known as C-
type lectin receptors (CLRs), recognize conserved carbohydrate 
structures, including mannose and galactose, found on the surface 
of many respiratory pathogens, such as Yersinia pestis, Mycobac-
terium tuberculosis, Streptococcus pneumoniae and influenza vi-
ruses. 10–14 CLRs also function as phagocytic receptors and include 
members of the mannose receptor family and DC-SIGN (dendritic 
cell-specific intercellular adhesion molecule-3-grabbing non-inte-
grin).15. Depending on the specific CLR, ligand binding initiates 
downstream signaling cascades that promote immune cell migra-
tion to the DLN as well as antigen processing and presentation via 
MHC I and/or MHC II to prime naïve T cells.16–20
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Abstract
C-type lectin receptors (CLRs) offer unique advantages for tailoring immune responses. Engagement of CLRs regulates antigen 
presenting cell (APC) activation and promotes delivery of antigens to specific intracellular compartments inside APCs for effi-
cient processing and presentation. In these studies, we have designed an approach for targeted antigen delivery by decorating the 
surface of polyanhydride nanoparticles with specific carbohydrates to provide pathogen-like properties. Two conserved carbohy-
drate structures often found on the surface of respiratory pathogens, galactose and di-mannose, were used to functionalize the sur-
face of polyanhydride nanoparticles and target CLRs on alveolar macrophages (AMφ), a principle respiratory tract APC. Co-cul-
ture of functionalized nanoparticles with AMφ significantly increased cell surface expression of MHC I and II, CD86, CD40 and 
the CLR CIRE over non-functionalized nanoparticles. Di-mannose and galactose functionalization also enhanced the expression 
of the macrophage mannose receptor (MMR) and the macrophage galactose lectin, respectively. This enhanced AMφ activation 
phenotype was found to be dependent upon nanoparticle internalization. Functionalization also promoted increased AMφ produc-
tion of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. Additional studies demonstrated the requirement of the MMR for 
the enhanced cellular uptake and activation provided by the di-mannose functionalized nanoparticles. Together, these data indicate 
that targeted engagement of MMR and other CLRs is a viable strategy for enhancing the intrinsic adjuvant properties of nanovac-
cine adjuvants and promoting robust pulmonary immunity.
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Several research groups have explored CLR targeting as a vaccine 
design strategy to promote efficient delivery of cargo to intracellular 
compartments responsible for antigen processing and presentation.21–29 
Many studies have demonstrated the effectiveness of using antibod-
ies22 or mannoproteins from pathogens26 to target CLRs and activate 
APCs. However, only a limited number report the use of carbohy-
drate-functionalized vaccine carriers as part of an improved adjuvant 
for intranasal vaccines.21, 24 Work published by Jiang et al. indicated 
that alveolar macrophages could recognize mannosylated chitosan mi-
croparticles when delivered intranasally.24 Unfortunately, mechanis-
tic studies demonstrating the engagement of the mannose receptor on 
AMφ by these particles were not performed. Here, we describe func-
tionalization of polyanhydride nanoparticles with two conserved car-
bohydrate structures commonly found on the surface of respiratory 
pathogens, di-mannose and galactose. We also investigate the mech-
anisms by which these functionalized polyanhydride nanoparticles are 
internalized by and influence the activation of AMφ.
2. Materials and methods
2.1. Materials
The chemicals needed for monomer synthesis, polymerization and nanopar-
ticle fabrication included 1,6-dibromohexane, triethylene glycol, 4-p-hy-
droxybenzoic acid, and 1-methyl-2-pyrrolidinone; these were purchased from 
Sigma–Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was obtained from 
Apollo Scientific (Cheshire, UK); toluene, sulfuric acid, acetonitrile, dimethyl 
formamide, acetic anhydride, methylene chloride, pentane, and potassium car-
bonate were obtained from Fisher Scientific (Fairlawn, NJ); p-carboxy ben-
zoic acid (99+%), and 1-methyl-2-pyrrolidinone, anhydrous (99+%) were 
purchased from Aldrich (Milwaukee, WI). For 1H NMR characterization, deu-
terated chemicals, including chloroform and dimethyl sulfoxide, were pur-
chased from Cambridge Isotope Laboratories (Andover, MA).
2.2. Monomer and polymer synthesis
The 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) monomers were synthesized as 
previously described.30, 31 Random copolymers with a 50:50 ratio of CPH and 
CPTEG were synthesized by melt polycondensation using an automated ro-
botic deposition apparatus operated with LabVIEW® (National Instruments) as 
previously described.31–35 The chemical structure of the polymers was charac-
terized via 1H NMR with a Varian VXR 300 MHz spectrometer (Varian Inc., 
Palo Alto, CA). Deuterated chloroform was used to dissolve the polymer and 
spectra were calibrated with respect to the chloroform peak (δ = 7.26 ppm). 
The polymer molecular mass was determined using gel permeation chroma-
tography (GPC). Samples were dissolved in HPLC-grade chloroform and 
separated on a Waters GPC chromatograph (Milford, MA) containing PL gel 
columns (Polymer Laboratories, Amherst, MA) comparing elution times to 
monodisperse polystyrene standards (Fluka, Milwaukee, WI).
2.3. High throughput synthesis of carbohydrates
A robotic set up was used for the iterative synthesis of linear α-1,2-linked 
di-mannose with a fluorous allyl group using fluorous solid phase extraction 
(FSPE) serving as a model to obtain the di-mannoside.21, 36–38 Carboxymethyl 
– di-mannose synthesis was performed by ozonolysis of the alkene39 followed 
by further oxidation with Jones reagent.37 Global deprotection under Birch re-
duction conditions40 produced the fully deprotected α-1,2-linked di-mannose. 
In addition, β-1-O-allylated galactose was prepared from β-penta-O-acetylated 
galactose using allyl alcohol and BF3.OEt2. Eight equivalents of NaIO4 uti-
lized under ruthenium-catalyzed Sharpless conditions41, 42 produced the de-
sired acid in 91% yield. Subsequent deacetylation under mild conditions using 
K2CO3 provided the desired fully deprotected galactoside.
2.4. High-throughput synthesis and characterization of functionalized 
nanoparticles
The fabrication of functionalized 50:50 CPTEG:CPH nanoparticles was per-
formed via an anti-solvent nanoencapsulation method using an automated ro-
botic deposition apparatus operated by LabVIEW®.32, 33, 43 Galactose and di-
mannose residues were conjugated to the surface of nanoparticles by a modified 
and optimized two-step amine carboxylic acid coupling reaction.21 Briefly, the 
first reaction was performed at 4 °C by incubating the nanoparticle suspension 
(100 mg/mL) with 12 equivalents (eq.) of 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC), 12 eq. of N-hydroxysuccinimide (NHS), 
and 10 eq. of ethylenediamine in nanopure water for 9 h with constant agita-
tion using a rotor shaker (Scientific Industries, Bohemia, NY). Nanoparticles 
were washed twice by centrifugation (10,000 rpm for 5 min) with the addition 
of nanopure water and sonication (at 40 Hz for 30 s). The second reaction was 
performed at 4 °C in a nanoparticle suspension (50 mg/mL) in nanopure wa-
ter with 12 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding saccha-
ride (i.e., galactose or di-mannose) or glycolic acid (linker between saccharide 
and nanoparticles; a control treatment for AMφ experiments) for 9 h with con-
stant agitation. Nanoparticles were washed once and dried under vacuum for 6 h. 
The automated set up was used to accurately dispense solutions of EDC, ethyl-
enediamine, and NHS for the first reaction, and solutions of EDC, NHS, and sac-
charides in the second reaction to increase the throughput of the process. Parti-
cle morphology was characterized by scanning electron microscopy (SEM, FEI 
Quanta 250, Kyoto, Japan), and hydrodynamic size and ζ-potential were deter-
mined by dynamic light scattering (DLS, Zetasizer Nano, Malvern Instruments 
Ltd., Worchester, UK). The saccharide concentration conjugated to the nanopar-
ticles was measured using a high throughput phenol sulfuric acid assay as previ-
ously described.21, 44
2.5. Mice
Wild type (WT) C57BL/6 (B6) mice were purchased from Harlan Laboratories 
(Indianapolis, IN) and macrophage mannose receptor deficient (MMR−/−) B6 
mice were a generous gift from Dr. Mary Ann McDowell of the University of 
Notre Dame. Mice were housed in specific pathogen-free conditions where all 
bedding, caging, and feed were sterilized prior to use. All animal procedures 
were conducted with the approval of the Iowa State University Institutional 
Animal Care and Use Committee.
2.6. Cell harvesting and culture
Murine alveolar macrophages (AMφ) from WT and MMR−/− B6 mice were har-
vested by bronchoalveolar lavage as previously described.6, 7, 45 Briefly, mice 
were euthanized and a sterile catheter inserted into the trachea of each mouse. 
Using a 1 mL syringe fitted with the catheter, 0.75 mL of room temperature, 
sterile PBS was gently infused into the lungs and then aspirated back into sy-
ringe. This process was repeated six times while externally massaging the chest. 
Following collection, lavage fluid was immediately placed on ice prior to cen-
trifugation (250× g, 10 min, 4 °C). Cell viability was then assessed using try-
pan blue. Cells were cultured in Complete Tissue Culture Medium (CTCM) con-
taining Dulbecco’s Modified Eagle Medium with 4.5 mg of glucose/mL, 2 mm 
l-glutamine, 100 U penicillin, 100 μg streptomycin/mL, 25 mm HEPES and 
10% fetal bovine serum in six-well plates at a density of 5 × 105 cells/well for 
8 h at 37 °C and 5% CO2. After 6 h of incubation, non-adherent cells were dis-
carded and adherent cells (>90%) were incubated overnight prior to treatment. 
Non-functionalized or functionalized nanoparticles were incubated with AMφ 
at a concentration of 0.125 mg/mL. Non-stimulated AMφ and AMφ stimulated 
with Escherichia coli O111:B4 lipopolysaccharide (LPS, 200 ng/mL Sigma–Al-
drich, St. Louis, MO) were used as negative and positive controls, respectively. 
After 48 h, supernatants were collected for quantification of cytokines and ni-
trites. Cells were stained for flow cytometric analysis. Bone marrow-derived 
macrophages (BMMφ) were derived as previously described.46, 47 Briefly, cells 
were obtained from WT and MMR−/− B6 mouse bone marrow and plated in a 
150 × 15 mm Petri dish with 30 mL CTCM supplemented with 30% L-cell con-
ditioned medium. After 2 days, an additional 20 mL of CTCM with 30% L-cell 
conditioned medium was added to the cultures. At day 6, adherent cell popu-
lations were harvested by placing the plates on ice for 20 min and then scrap-
ing with a cell scraper. After washing in PBS, live cells were counted and re-
suspended in CTCM prior to treatment with nanoparticles and stimulants as 
described for the AMφ.
2.7. Cell surface marker evaluation
Flow cytometric evaluation of cell surface markers was performed by mod-
ifying a previously described protocol.48 Briefly, cells were washed in 2 mL 
of fluorescence-activated cell sorting buffer (FACS buffer, 0.1% sodium azide 
and 0.1% bovine serum albumin in phosphate buffer saline). Fcγ receptors 
were blocked with PBS containing 100 μg/mL rat anti-mouse CD16/CD32 an-
tibody (BD Bioscience, San Diego, CA) and 1 mg/mL rat IgG for 30 min at 
4 °C to prevent non-specific binding. AMφ were incubated with appropriate 
antibodies or isotype controls for 15 min on ice. Antibodies used for assess-
ment of activation included phycoerythrin (PE)-Cy7 conjugated anti-mouse 
F4/80 (clone BM8), fluorescein isothiocyanate (FITC)-conjugated anti-mouse/
rat MHC II (I-A/I-E, clone M5/114.15.2), allophycocyanin (APC) anti-mouse 
CD40 (clone 1C10) and PE conjugated anti-mouse MHC I (H-2Kb, clone 
AF6-88.5.5.3). These antibodies and their respective isotype controls were 
purchased from eBioscience (San Diego, CA). APC-Cy7 anti-mouse CD86 
(clone GL-1) was purchased from Biolegend (San Diego, CA). Antibodies 
used to evaluate CLR expression included F4/80, biotin conjugated anti-mouse 
4764 Ch av ez-sa n To s C o y e T a l.  i n Bi o m at er i al s  33 (2012) 
CD209 (clone 5H10) and PE-Texas red conjugated streptavidin purchased 
from BD Biosciences, FITC anti-mouse CD206 (MMR, clone MR5D3) pur-
chased from Biolegend and PE-CD301a/b (MGL1/2, affinity purified PAb cat-
alog # FAB4297P) purchased from R&D systems (Minneapolis, MN). Sam-
ples were acquired using a FACSAria III flow cytometer (BD Biosciences) and 
the data were analyzed using FlowJo software (TreeStar Inc., Ashland, OR).
2.8. Nanoparticle internalization
At the time of fabrication, nanoparticles were loaded with cadmium selenide 
quantum dots (QDs; emission at 630 nm) prior to functionalization. The QDs 
were kindly provided by Dr. Aaron Clapp of Iowa State University. QD-loaded 
functionalized and non-functionalized nanoparticles were used to stimulate 
AMφ for 48 h. Cells were then analyzed by flow cytometry to identify the 
populations of AMφ that had phagocytosed nanoparticles (i.e., nanoparticle-
positive versus nanoparticle-negative) as described previously.49 A QD con-
trol (background) was used to account for “false positives” because of QDs 
released due to nanoparticle degradation. QD-loaded, functionalized (e.g., di-
mannose) and non-functionalized nanoparticles were incubated in cell culture 
medium for 48 h. After centrifugation (250× g, 10 min, 4 °C), supernatants 
were added to AMφ. After 48 h, the fluorescence registered for these control 
groups was considered as background. Cells were labeled with the above-de-
scribed F4/80, MHC II, CD40, CD86 and CD301a/b antibodies as wells as 
with Pacific blue anti-mouse MHC I (H-2Kb, clone AF6-88.5) purchased from 
Biolegend, biotin anti-mouse CD209 and PerCP-Cy5.5 conjugated streptavi-
din purchased from eBioscience.
2.9. Cytokine and reactive nitrogen species assays
After stimulation for 48 h with non-functionalized or functionalized nanopar-
ticles, cell-free supernatants were assayed for IL-1β, IL-10, TNF-α, IL-6, and 
IL-12p40 using a multiplex cytokine assay in conjunction with a Bio-Plex 200 
System (Bio-Rad, Hercules, CA) as described elsewhere.33 Griess Reagent 
(Invitrogen, Carlsbad, CA) was used according to the manufacturer’s speci-
fications to determine nitrite concentration as an indirect method to measure 
production of reactive nitrogen species.
2.10. Statistical analysis
The statistical software JMP®7 was used to analyze all data. Tukey’s HSD 
was used to determine significant differences among treatments. A student’s T 
test was employed to determine the significant differences between AMφ har-
vested from WT versus MMR−/− mice and between nanoparticle positive and 
negative AMφ. All p values < 0.05 were considered significant.
3. Results
3.1. Synthesis and characterization of functionalized polyanhy-
dride nanoparticles
Amphiphilic 50:50 CPTEG:CPH copolymer was synthesized as de-
scribed previously.31 The molecular weight (Mw) of the copolymer 
was 8000 Da and 1H NMR spectra of the copolymer were consis-
tent with previously published data.31, 33, 35 Particle morphology was 
evaluated by SEM and was found to be consistent with previously 
published results (c.f. References [21], [33], & [43]; and data not 
shown). The average diameter of the non-functionalized nanoparti-
cles was 163 ± 24 nm with a ζ-potential of −23 ± 2.5 mV (consis-
tent with the presence of carboxylic acids on the surface). The gly-
colic acid (linker only) functionalized nanoparticles had an average 
diameter of 261 ± 44 nm and a ζ-potential of 20 ± 2.7 mV, while 
di-mannose functionalized and galactose functionalized nanoparti-
cles had average diameters of 271 ± 40 nm and 263 ± 44 nm, respec-
tively, with ζ-potentials of 26 ± 1.9 mV. The positive charges of the 
functionalized particles were consistent with previously published 
data21 and are attributed to the presence of free ethylenediamine 
groups on the surface of the particles. Measuring the ζ-potential of 
ethylenediamine-functionalized nanoparticles (determined to be 
31 ± 3.6 mV) further corroborated this result. These data indicate 
that partial capping of the ethylenediamine groups occurs when the 
saccharide is conjugated in the second reaction of the functionaliza-
tion process. The di-mannose and galactose concentrations attached 
to the nanoparticles were normalized to the total mass of nanoparti-
cles. The di-mannose concentration was 13.2 ± 3.5 μg/mg, consistent 
with previous work.21 The galactose concentration conjugated to the 
nanoparticles was 15.2 ± 4.7 μg/mg.
3.2. Influence of functionalized polyanhydride nanoparticles on 
AMφ activation
Previous work from our laboratories has highlighted the intrinsic 
adjuvant activity of polyanhydride micro and nanoparticles, as ev-
idenced by their ability to activate DCs.48, 49 In the current study, 
we observe, for the first time, increased expression of surface mark-
ers associated with antigen processing and presentation (MHC I and 
II) and T cell co-stimulation (CD86 and CD40) in primary AMφ 
cultured with non-functionalized (NF) polyanhydride nanoparti-
cles as compared to non-stimulated AMφ (Figure 1A–D). Cultur-
ing AMφ with non-functionalized polyanhydride nanoparticles also 
enhanced surface expression of CLRs (MMR, MGL and CIRE) in 
comparison to non-stimulated AMφ and AMφ stimulated with LPS 
(Figure 1E–G).
Functionalization of polyanhydride nanoparticles with either di-
mannose or galactose provided a significant enhancement in the ex-
pression of MHC I and CD40 on the surface of AMφ in compari-
son to treatment with either non-functionalized particles or particles 
functionalized with only glycolic acid, the linker used to attach the 
carbohydrates to the nanoparticles (Figure 1A and D). AMφ MHC 
II and CD86 expression was significantly increased over non-func-
tionalized particles regardless of the nanoparticle functionalization 
(Figure 1B and C), with the greatest enhancement in MHC II ob-
served on AMφ co-cultured with di-mannose functionalized parti-
cles (Figure 1B). As compared to non-functionalized nanoparticles, 
expression of the MMR on AMφ was only significantly enhanced 
upon incubation with di-mannose functionalized nanoparticles (Fig-
ure 1E). Similarly, co-culture with galactose functionalized nanopar-
ticles significantly increased AMφ MGL expression (Figure 1F). No 
significant enhancement in CIRE expression was observed when 
AMφ were incubated with functionalized versus non-functionalized 
nanoparticles (Figure 1G).
Together, these observations indicate that carbohydrate func-
tionalization of polyanhydride nanoparticles enhanced AMφ activa-
tion as compared to non-functionalized particles. In some instances 
(e.g., MHC II and CD86 expression), functionalization with only the 
glycolic acid linker was sufficient to activate AMφ, indicating that 
nanoparticle surface charge contributes to AMφ activation. Finally, 
AMφ co-cultured with di-mannose or galactose functionalized par-
ticles exhibited enhanced cellular activation profiles that were com-
parable or superior to those observed in AMφ stimulated with LPS.
3.3. Relationship between functionalized polyanhydride nanoparti-
cle internalization and CD40 expression on AMφ
Phagocytosis of pathogenic bacteria is an important step associ-
ated with innate immune mechanisms and results in activated mac-
rophages.50, 51 We, therefore, evaluated the relationship between 
nanoparticle internalization and AMφ activation.49 Internalization of, 
and not just association with, nanoparticles by AMφ was confirmed 
by confocal microscopy (data not shown). Two populations of cells 
were identified—cells that internalized nanoparticles (QD-loaded 
nanoparticle-positive) and cells that did not internalize particles 
(nanoparticle-negative). Internalization of nanoparticles, regardless 
of functionalization status, was found to be required for the enhanced 
expression of CD40 on AMφ (Figure 2B), but not for the expression 
of CD86 (Figure 2A), MHC I, or MHC II (data not shown).
Interestingly, the nanoparticle-positive cells that internalized di-
mannose but not galactose-functionalized nanoparticles expressed 
significantly greater levels of the MMR as compared to nanoparti-
cle-negative cells (Figure 2C). A similar relationship was observed 
for galactose but not di-mannose functionalized particles and MGL 
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Figure 1. Functionalization of polyanhydride nanoparticles enhanced AMφ expression of MHC, T cell co-stimulatory molecules, and CLRs. After stimulation 
with non-functionalized (NF) or functionalized nanoparticles for 48 h, AMφ were harvested and analyzed by flow cytometry for surface expression of (A) MHC 
I, (B) MHC II, (C) CD86, (D) CD40, (E) MMR, (F) MGL, or (G) CIRE. LPS stimulated and non-stimulated cells (NS) were used as positive and negative con-
trols, respectively. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. Treatments with different letters are sig-
nificantly different from one another at p < 0.05. MFI = mean fluorescence intensity.
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expression (Figure 2D). A significant increase in CIRE was ob-
served on AMφ that internalized either non-functionalized or di-
mannose functionalized nanoparticles but not nanoparticles that 
were functionalized with galactose or only the glycolic acid linker 
(Figure 2E). Together, these data support an association between in-
ternalization of nanoparticles functionalized with specific carbohy-
drates and the enhanced expression of the cognate receptor specific 
for that carbohydrate.
3.4. Influence of functionalized polyanhydride nanoparticles on 
AMφ pro-inflammatory cytokine secretion
Previous reports from our laboratory have described the ability of 
non-functionalized polyanhydride nanoparticles to enhance secre-
tion of pro-inflammatory cytokines from APCs.32, 48 In this present 
work, we sought to extend our findings by asking if functionalization 
Figure 2. Internalization of functionalized polyanhydride nanoparticles was required for upregulation of CD40 expression on AMφ. Percent of AMφ that did not 
internalize (nanoparticle-negative; □) or did internalize (nanoparticle-positive; ■) nanoparticles after 48 h that were also positive for (A) CD86, (B) CD40, (C) 
MMR, (D) MGL, or (E) CIRE. Data are expressed as the mean ± the SEM of three independent experiments performed in triplicate. * Represents a statistically 
significant difference between nanoparticle-positive and nanoparticle-negative populations within a treatment at p < 0.05.
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with specific carbohydrates provides additional stimulatory capacity 
to the polyanhydride nanoparticles. Indeed, di-mannose functional-
ized nanoparticles significantly elevated AMφ production of IL-1β as 
compared to all nanoparticle treatments (Figure 3A). Functionaliza-
tion with either di-mannose or the glycolic acid linker but not ga-
lactose enhanced AMφ secretion of TNF-α (Figure 3B). Di-mannose 
modification of the nanoparticles provided no additional benefit in 
terms of increasing IL-6 or IL-12p40 production (Figure 3C and D). 
Of note, functionalization with either the glycolic acid linker alone or 
galactose diminished the secretion of IL-12p40 observed when AMφ 
were co-cultured with non-functionalized nanoparticles (Figure 3D). 
No IL-10 was detected in the culture supernatants of any AMφ co-
Figure 3. Carbohydrate functionalization of nanoparticles differentially influenced pro-inflammatory cytokine secretion. After stimulation with non-functional-
ized (NF) or functionalized nanoparticles for 48 h, culture supernatants were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL-12p40. LPS 
stimulated and non-stimulated cells (NS) were used as positive and negative controls, respectively. Mean cytokine production for AMφ stimulated with LPS: 
IL-1β = 1021.7 ± 66.5 pg/mL, IL-6 = 7804.3 ± 101.2 pg/mL, TNF-α = 5711.5 ± 181.7 pg/mL, and IL-12p40 = 3637.8 ± 111.6 pg/mL. (E) Nitrate concentra-
tion was measured in culture supernatants via a Griess assay as an indirect method to quantify production of reactive nitrogen species. Data are expressed as 
the mean ± the SEM of three independent experiments performed in triplicate. Treatments with different letters are significantly different from one another at 
p < 0.05.
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cultured with nanoparticles (data not shown). As shown in Figure 3E, 
the di-mannose functionalize particles induced significantly more re-
active nitrogen species when compared to the non-stimulated group 
(negative control). All the other nanoparticle groups induced levels 
of reactive nitrogen species that were similar when compared to the 
non-stimulated group (negative control).
3.5. Di-mannose functionalized nanoparticles and engagement of 
the MMR
The data depicted in Figure 2 demonstrated that nanoparticle inter-
nalization was required for increased CD40 and CLR expression. 
Furthermore, we demonstrated that AMφ activation by function-
alized nanoparticles was also a consequence of nanoparticle inter-
nalization (Figs. 1and 3). Using flow cytometry, we found that any 
functionalization of the nanoparticles enhanced uptake by AMφ as 
compared to non-functionalized particles (Figure 4, open bars).
To evaluate the role of the MMR on the uptake of di-mannose 
functionalized nanoparticles, we isolated AMφ from MMR-deficient 
(MMR−/−) mice and co-cultured them with functionalized nanopar-
ticles. As compared to wild type (WT) AMφ, a significant decrease 
in the number of internalized nanoparticles was only observed when 
di-mannose functionalized nanoparticles were co-cultured with 
MMR−/− AMφ (Figure 4, open versus closed bars). These data indi-
cate that di-mannose functionalization of nanoparticles confers a spe-
cific interaction of the nanoparticles with the MMR that contributes 
to their enhanced internalization. In contrast, nanoparticles function-
alized with galactose or only the glycolic acid linker are internalized 
via other, non-MMR-dependent pathways. Similar results were ob-
tained using bone marrow-derived macrophages (BMMφ; Supple-
mental Figure 1).
Consistent with the internalization data, co-culture of WT AMφ 
with di-mannose functionalized nanoparticles significantly increased 
the expression of MHC I, MHC II, CD86 and CD40 in comparison to 
that observed for MMR−/− AMφ (Figure 5A–D). Similarly, MMR−/− 
AMφ secreted significantly less IL-1β and IL-6 as compared to WT 
AMφ when co-cultured with di-mannose functionalized nanoparti-
cles (Figure 6A and C). As compared to WT AMφ, reduced levels 
of CIRE expression (Figure 5E) and TNF-α and IL-12p40 secretion 
(Figure 6B and D) were also observed in MMR−/− AMφ co-cultured 
with di-mannose functionalized as well as with non-functionalized 
nanoparticles. In contrast, WT and MMR−/− AMφ produced similar 
amounts of all cytokines measured following stimulation with LPS, 
indicating that MMR−/− AMφ were functionally capable of cytokine 
production (data not shown). Likewise, the absence of the MMR had 
no negative effect on the increased surface marker expression or cy-
tokine production observed when AMφ were co-cultured with galac-
tose functionalized nanoparticles (Figures 5 & 6), indicating that ga-
lactose functionalized particles do not require the MMR to promote 
AMφ activation. To rule out that our observations were unique to 
AMφ, these analyses were performed using BMMφ and similar re-
sults were obtained (Supplemental Figures 2 & 3). Together, these 
data support the concept that di-mannose functionalized nanoparti-
cles enhance AMφ activation by engaging the MMR.
4. Discussion
In the present work, we have designed an approach to targeted an-
tigen delivery by functionalizing the surface of polyanhydride 
nanoparticles with specific carbohydrates to enable the nanoparticles 
to engage C-type lectin receptors on AMφ. Our rationale is that re-
ceptor-mediated engagement of nanoparticles will enhance their up-
take and the activation of AMφ, leading to the induction of robust 
immune responses in the respiratory tract.
Co-culture of functionalized nanoparticles with AMφ signifi-
cantly increased cell surface expression of MHC I and II, CD86, 
CD40 and the C-type lectin receptor CIRE over non-functionalized 
nanoparticles (Figure 1A–D and G). Di-mannose and galactose func-
tionalization also enhanced the expression of the MMR and MGL, 
respectively (Figure 1E and F). Carbohydrate modification also sig-
nificantly increased uptake of the nanoparticles by AMφ. Moreover, 
the enhanced expression of CD40 on AMφ incubated with function-
alized nanoparticles was found to be dependent upon nanoparticle 
internalization (Figure 2). The presence of nanoparticles in the co-
culture was sufficient for enhancement of certain activation markers 
(i.e., CD86, MHC I, and MHC II), while internalization was required 
for the expression of CD40. Our results show that the targeting of 
the C-type lectin receptors MMR, MGL, and CIRE resulted in a 
higher percentage of AMφ that internalize nanoparticles (Figure 4, 
open bars). This enhanced internalization may improve antigen de-
livery to antigen processing compartments52–54 and the enhancement 
of the expression of co-stimulatory receptors (i.e., CD86 and CD40) 
as shown in Figure 1.
Nanoparticle internalization also played a critical role in the en-
hanced expression of CLRs (Figure 2C–E). MMR expression was in-
creased on AMφ following co-culture with mannose-functionalized 
nanoparticles (Figure 1E), and this enhanced expression required in-
ternalization of the nanoparticles (Figure 2C). Similar results were 
observed for MGL (Figs. 1F and 2D). The expression of the CIRE 
receptor was enhanced by most of the nanoparticle formulations, but 
only cells that internalized non-functionalized and di-mannose func-
tionalized nanoparticles showed increased expression of this marker 
(Figs. 1G and 2E). Several reports have shown that CLRs undergo 
internalization and recycling between the plasma membrane and the 
endosomal compartments.55–57 Our results indicate that positive self-
regulation of specific CLRs occurs upon ligand recognition, subse-
quently increasing the expression of these markers.
Figure 4. Di-mannose functionalized nanoparticles enhanced internaliza-
tion by engaging the macrophage mannose receptor on AMφ. Percent of wild 
type (□) and MMR-deficient (MMR−/−;■) AMφ that internalized nanoparti-
cles after 48 h. Data are expressed as the mean ± the SEM of three indepen-
dent experiments performed in triplicate. * represents a statistically signifi-
cant difference between wild type and MMR−/− AMφ within a treatment at 
p < 0.05. # represents a statistically significant difference from the non-func-
tionalized nanoparticle treatment group for wild type AMφ. ^ represents a sta-
tistically significant difference from the non-functionalized nanoparticle treat-
ment group for MMR−/− AMφ.
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The production of pro-inflammatory cytokines is essential for the 
activation of macrophages to stimulate their anti-microbial properties 
and for them to initiate adaptive immune responses.58 Di-mannose 
functionalization enhanced the production of IL-12p40, IL-1β and 
TNF-α (Figure 3A–D). These results are in agreement with studies 
demonstrating that the targeting of MMR resulted in the production 
of pro-inflammatory cytokines through the activation of NF-κB.59 
Although the production of pro-inflammatory cytokines was en-
hanced by the di-mannose functionalization, the levels secreted were 
modest enough to allay concerns about chronic inflammation in the 
Figure 5. Di-mannose functionalized nanoparticles enhanced AMφ expression of MHC, T cell co-stimulatory molecules and CLRs by engaging the macrophage 
mannose receptor. After stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 h, wild type (□) and MMR-deficient (MMR−/−;■) AMφ 
were harvested and analyzed by flow cytometry for surface expression of (A) MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. Non-stimulated 
(NS) cells were used as negative controls. Data are expressed as the mean ±  the SEM of three independent experiments performed in triplicate. * Represents a 
statistically significant difference between wild type and MMR−/− AMφ within a treatment at p < 0.05. MFI = mean fluorescence intensity. # Represents a statisti-
cally significant difference from the NS cells for wild type AMφ. ^ Represents a statistically significant difference from the NS cells for MMR−/− AMφ.
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respiratory tract following intranasal administration. The galactose 
functionalized nanoparticles resulted in an enhanced production of 
cytokines in comparison with the non-stimulated AMφ, but at lower 
levels than the non-functionalized nanoparticles, particularly for IL-
12p40. The release of pro-inflammatory cytokines when the cells 
were treated with galactose-functionalized particles was similar to 
that of the non-functionalized nanoparticles. These results are consis-
tent with previous studies suggesting that galactose motifs enhanced 
the production of cytokines such as IL-12p40 and TNF-α, but not to 
the levels obtained when mannose motifs are used.59, 60
The elevated production of reactive nitrogen species has been re-
lated to chronic inflammation and cancers of several organs, includ-
ing lungs.61 Such a response may be needed to combat an infection; 
however it would not be desirable consequence following admin-
istration of an intranasal vaccine. As shown in Figure 3E, all the 
nanoparticle groups induced levels of reactive nitrogen species that 
were similar when compared to the non-stimulated group (negative 
control). Collectively, these data demonstrate that di-mannose func-
tionalization significantly enhanced the expression of cell surface 
makers and the production of relevant cytokines, leading to an acti-
vated phenotype of AMφ that is necessary for the initiation of robust 
mucosal immune responses.
To further assess the role of MMR-specific recognition of di-
mannose functionalized nanoparticles, studies were performed using 
AMφ harvested from MMR−/− mice. Statistically significant differ-
ences were observed in the internalization of di-mannose function-
alized nanoparticles between AMφ harvested from wild type and 
MMR−/− mice (Figure 4), indicating that the MMR significantly 
contributes to the enhanced uptake observed when polyanhydride 
nanoparticles are functionalized with di-mannose. Enhanced up-
take was also observed for glycolic acid functionalized nanoparti-
cles as compared to non-functionalized nanoparticles. This may be 
attributed to the hydrophilic properties conferred by the mannose 
and glycolic acid groups to the surface of the particles that may in-
crease their internalization in comparison to more hydrophobic sur-
faces (i.e., non-functionalized nanoparticles). This observation is 
consistent with previously published data that shows that hydrophilic 
chemistries are more readily internalized by AMφ and DCs.49, 62 As 
expected, the absence of the MMR did not negatively affect the en-
hanced uptake of galactose-functionalized nanoparticles. The en-
hanced AMφ activation phenotype (i.e., above that induced by non-
functionalized nanoparticles) observed following co-culture with 
di-mannose functionalized nanoparticles was also found to be depen-
dent upon the presence of the MMR (Figures 5 & 6). This finding 
Figure 6. Di-mannose functionalized nanoparticles enhanced AMφ pro-inflammatory cytokine production by engaging the macrophage mannose receptor. Af-
ter stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 h, culture supernatants from wild type (□) and MMR-deficient (MMR−/−;■) 
AMφ were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL-12p40. Non-stimulated (NS) cells were used as a negative control. Data are ex-
pressed as the mean ± the SEM of three independent experiments performed in triplicate. * Represents a statistically significant difference between wild type and 
MMR−/− AMφ within a treatment at p < 0.05. # Represents a statistically significant difference from the NS cells for wild type AMφ. ^ Represents a statistically 
significant difference from the NS cells for MMR−/− AMφ.
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suggests that specific engagement of the MMR further enhances the 
expression of cell surface markers and cytokine production. As indi-
cated before, mannose is a component of the surface of many respi-
ratory pathogens, including Y. pestis, M. tuberculosis, S. pneumoniae 
and influenza viruses, indicating that the MMR may be involved in 
how these pathogens are recognized by macrophages and DCs. Typ-
ically, upon encountering pathogens, these APCs upregulate expres-
sion of antigen presentation and co-stimulatory molecules as well as 
secrete cytokines to efficiently prime the naïve T cells that help ac-
tivate B cells. Our results indicate that di-mannose functionalized 
nanoparticles may have pathogen-like characteristics with respect to 
their APC activation abilities.
Together, these studies indicate that CLR targeting may be an ef-
fective strategy to activate AMφ that, in turn, may be critical to the 
implementation of efficacious intranasal vaccines. Functionalized 
nanoparticles provide a versatile and robust platform that facilitates 
enhanced expression of antigen presentation and co-stimulatory mol-
ecules and secretion of the cytokines responsible for initiating and 
maintaining adaptive immunity. By innovatively engaging mecha-
nisms or pathways that activate APCs, these studies indicate that it is 
feasible to develop an immunization regimen that safely and effica-
ciously induces protective immunity without the need to induce ad-
verse or deleterious host responses.
5. Conclusions
The approach outlined in this present work demonstrates that ratio-
nal design of efficacious vaccine adjuvants can be achieved by tar-
geting CLRs on APCs. Specifically, we describe the functionalization 
of polyanhydride nanoparticles with two conserved carbohydrate 
structures commonly found on the surface of respiratory pathogens, 
di-mannose and galactose. The addition of these carbohydrates sig-
nificantly enhanced the intrinsic adjuvant activity of our polyanhy-
dride nanovaccine platform by further upregulating AMφ surface 
expression of MHC I and II, CLRs, the T cell co-stimulatory mol-
ecules CD86 and CD40 and the secretion of pro-inflammatory cyto-
kines. Moreover, we demonstrate that the macrophage mannose re-
ceptor (MMR) played a central role in the activation of AMφ as well 
as the uptake of di-mannose functionalized polyanhydride nanoparti-
cles. These studies provide important insights into the design, mod-
ification, and rational selection of intranasal vaccine carriers and/or 
adjuvants.
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Appendix A, containing Supplemental Figures 1–3, follows.
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Supplemental Figure 1. Di-mannose functionalized nanoparticles enhanced internalization 
by engaging the macrophage mannose receptor on bone marrow-derived macrophages 
(BMMɸ). Percent of wild type () and MMR-deficient (MMR-/-; ) BMMɸ that internalized 
nanoparticles after 48 h. Data are expressed as the mean ± the SEM of three independent 
experiments performed in triplicate. * represents a statistically significant difference between wild 
type and MMR-/- BMMɸ within a treatment at p < 0.05. # represents a statistically significant 
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difference from the non-functionalized nanoparticle treatment group for wild type BMMɸ. ^ 
represents a statistically significant difference from the non-functionalized nanoparticle treatment 
group for MMR-/- AMɸ. 
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Supplemental Figure 2. Di-mannose functionalized nanoparticles enhanced bone marrow-
derived macrophage (BMMɸ) expression of MHC, T cell co-stimulatory molecules and 
CLRs by engaging the macrophage mannose receptor. After stimulation with non-
functionalized (NF) or functionalized nanoparticles for 48 h, wild type () and MMR-deficient 
(MMR-/-; ) BMMɸ were harvested and analyzed by flow cytometry for surface expression of (A) 
MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. Non-stimulated (NS) cells were 
used as negative controls. Data are expressed as the mean ± the SEM of three independent 
experiments performed in triplicate. * represents a statistically significant difference between wild 
type and MMR-/- BMMɸ within a treatment at p < 0.05. MFI = mean fluorescence intensity. # 
represents a statistically significant difference from the NS cells for wild type AMɸ. ^ represents a 
statistically significant difference from the NS cells for MMR-/- AMɸ. 
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Supplemental Figure 3. Di-mannose functionalized nanoparticles enhanced bone marrow-
derived macrophage (BMMɸ) pro-inflammatory cytokine production by engaging the 
macrophage mannose receptor. After stimulation with non-functionalized (NF) or 
functionalized nanoparticles for 48 h, culture supernatants from wild type () and MMR-deficient 
(MMR-/-; ) BMMɸ were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, or (D) IL-
12p40. Non-stimulated (NS) cells were used as a negative control. Data are expressed as the 
mean ± the SEM of three independent experiments performed in triplicate. * represents a 
statistically significant difference between wild type and MMR-/- BMMɸ within a treatment at p < 
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0.05. # represents a statistically significant difference from the NS cells for wild type AMɸ. ^ 
represents a statistically significant difference from the NS cells for MMR-/- AMɸ. 
